#medicalscienceliaison

[sblsunita]

Derma Franchise Company in India

EOS Dermaceutical is one of the best Derma Franchise Company in India that is working with the ambition to improve the health of people by delivering excellent and qualitative derma product range. We are functioning to fulfil two main objectives.

The first one is to improve the quality of health of patients by offering them the best quality derma products and,

The second objective is to make our quality derma product range available at various districts of India. To know more about our product range , visit our wensite

https://solacebiotech.in/blog/derma-franchise-company-in-india/ or for business Opportunities requirement contact at 9355955555,9541101111

.

.

.

#mbbs #nurse #pharmaceutics #phd #bhfyp #pharmaindustry #drug #microbiology #pharmaceuticalindustry #pharmacymemes #hospital #clinicalresearch #medicalaffairs #technology #pharmacistlife #medstudent #coronavirus #bpharm #medicalstudent #ntagpat #memes #medschool #pharmajobs #clinicaltrials #farmaceutica #lifesciences #medicalscienceliaison #farmacista #molecularbiology #instagram

[fromsciencetopharma]

Hallmarks of Cancer: New Dimensions The review everyone is reading right now... An updated perspective on the "Hallmarks of Cancer" from Douglas Hanahan. In the review the author introduces new hallmarks and enabling characteristics of cancer: “unlocking phenotypic plasticity,” “nonmutational epigenetic reprogramming,” “polymorphic microbiomes,” and “senescent cells” https://lnkd.in/d4yc2a4w #cancerresearch #cancer #oncology #science #MSL #fstp #medicalaffairs #medicalscienceliaison #BoardcertifiedMSL #bcmslcert https://www.instagram.com/p/CYvyseIp0Kl/?utm_medium=tumblr

[fromsciencetopharma]

GSK to provide malaria vaccines for Gavi eligible countries #GSK #malaria #greatnews “This follows the World Health Organisation’s (WHO) recommendation for the broader use of GSK’s RTS,S/AS01e to combat the issue of childhood illness and deaths from malaria in children living in sub-Saharan Africa and other regions with moderate to high transmission, as defined by WHO. The new development will arm healthcare providers with a vital tool to address the steep rise of malaria cases in children living in Africa. Africa continues to have the heaviest malaria burden and African children are at highest risk of dying of malaria. Over 260,000 African children under the age of five died from malaria in 2019 and COVID-19 has only exacerbated this disease burden. This highlights the ever-growing, urgent need for new and innovative tools to combat malaria. RTS,S/AS01e is the result of over 35 years of research led by GSK, with nonprofit health organisation PATH and other partners. It is the first and only malaria vaccine to have been shown in pivotal long-term clinical trials to significantly reduce malaria in children.” #MSL #FSTP #BCMSLcert #BoardCertifiedMSL #medicalscienceliaison medical science liaison #Medicalaffairs medical affairs #Pharmacist #phd https://lnkd.in/eADTdp4Z https://www.instagram.com/p/CXNh1popk9u/?utm_medium=tumblr

[fromsciencetopharma]

More growth on the way for CSL? Australian giant in talks to buy Vifor for $7.1B: report #csl #Vifor #acquisition “Australian biotech giant CSL is negotiating with Vifor Pharma Group to acquire the Swiss company for A$10 billion ($7.1 billion), says the Australian Financial Review. The acquisition would become the largest ever for CSL. The companies were in talks in March, the Australian publication reported, but the talks have now become more serious. The report comes less than six months after Abbas Hussain left the board at CSL to become the CEO of Vifor, an 88-year-old specialty pharmaceutical company. Vifor markets iron deficiency, nephrology and cardio-renal products in more than 100 countries worldwide, its website says. Addressing "market speculations" Thursday, the company said it "systematically reviews options that can strengthen its market position and/or accelerate the growth of the company both organically and through partnerships and acquisitions." CSL, which has no rivals as Australia’s largest company in the biopharma industry, has made several major acquisitions over the last few decades. Its $275 million purchase of Novartis’ flu vaccine business in 2014 help build CSL’s Seqirus into one of the top flu shot players in the world. Beyond that, its buyouts of Florida-based Nabi and Zentrallaboratorium twenty years ago helped make CSL the world’s premier plasma collection company. A $965 million buy of Aventis Behring in 2003 helped broaden CSL's product portfolio” Early this year, CSL began producing AstraZeneca’s COVID-19 vaccine. It also manufactured the University of Queensland’s investigational COVID-19 shot, until the project was discontinued. Vifor’s largest shareholder is Swiss billionaire Martin Ebner, who owns Helvetic Airlines and BZ Bank and the BZ Group.” #MSL #FSTP #BCMSLcert #BoardCertifiedMSL #medicalscienceliaison medical science liaison #Medicalaffairs medical affairs #Pharmacist #phd https://lnkd.in/eF8UdJZJ https://www.instagram.com/p/CXHgEV8Bj7l/?utm_medium=tumblr

[fromsciencetopharma]

Vertex, needing research spark, finds promising results in small study of kidney disease drug #Vertex #kidneydisease “ The biotech, which has been stung by recent clinical setbacks, plans to soon advance the medicine into late-stage testing. Vertex Pharmaceuticals will quickly advance an experimental drug for a genetic form of kidney disease into late-stage testing, after results from a small study surpassed the company's expectations. The findings are early evidence for a new way of treating the condition, called focal segmental glomerulosclerosis, by targeting gene variations first identified as significant a little more than a decade ago. They're also a much-needed win for Vertex, which, despite having successfully developed four effective drugs for cystic fibrosis, has struggled to convince investors it can repeat its success in other diseases. Focal segmental glomerulosclerosis, or FSGS, describes scarring of the kidney that impairs the organ's ability to filter blood, resulting in high levels of protein in urine. It has a range of causes, such as viral infections or drug toxicity, and is one of several ways kidney disease can develop. Patients are typically treated with blood pressure medicines and steroids, which offer limited benefit. In 2010, a group of researchers in the U.S. and Belgium discovered that two variants in a gene called APOL1 dramatically increase the risk of kidney disease, including FSGS specifically, and can lead to more aggressive progression. Though Vertex still has much to prove, two of its experimental drug programs have shown signs of promise. In October, the company reported encouraging findings from the first patient given a stem cell-based diabetes treatment. And the study results released by the company Wednesday suggest that it's on the right track with APOL1 and kidney disease as well. #MSL #FSTP #BCMSLcert #BoardCertifiedMSL #medicalscienceliaison medical science liaison #Medicalaffairs https://www.instagram.com/p/CW9HeQmhP7U/?utm_medium=tumblr

[fromsciencetopharma]

MSL DISEASE EXPERTISE TEST – CLINICAL TRIALS Are you an MSL or want to become an MSL and do you think you are a disease matter expert in your disease area? from SCIENCE to PHARMA (FSTP) - MSL global online training and Karger Publishers have developed the “MSL disease expertise test” to quickly test your disease expertise knowledge for a range of diseases. Click below to test if you are a true disease expert in CLINICAL TRIALS https://lnkd.in/epG3GBh Or click the below link if you want to take any other disease expertise tests we have developed. https://lnkd.in/e6dtadE You will receive an automatic email with your certificate and score (if you score >75%). Have fun and good luck! #MSLexcellence #MSLcert #FSTP #medicalscienceliaison #themslcommunity #karger Geoff Covey #clinicaltrials #clinicalresearch #clinicalresearchassociate #clinicalresearchcoordinator #clinicalresearchers -Click on the “thumbs up” symbol if you scored >80% -Click on the “clapping hand” symbol if you scored 100% -Post your score in a comment below https://www.instagram.com/p/CWJiirohf9J/?utm_medium=tumblr

[fromsciencetopharma]

LEARN HOW TO BECOME A MEDICAL SCIENCE LIAISON Are you a pharmacist, scientist, PhD or medical doctor and want to become a Medical Science Liaison? Join our next #freeMSLwebinar to learn more about the MSL role and how to transition WITHOUT pharmaceutical industry experience. This webinar will cover everything you need to know to become an #MSL. Click on the below link to reserve your #MSLwebinar seat. Spots are filling fast https://lnkd.in/etJsiyw from SCIENCE to PHARMA Providing excellence in Medical Affairs education #MSL #MSLTraining #BoardcertifiedMSL #BCMSLcert #BCMSLcert #AspiringMSL #MedicalAffairs #pharma #MD #PharmD #MSc #Pharmacist #Pharmacists #Postdoc #postdocs #postdoctoral #PhD #PhDs #Medicalscienceliaison #MSLS #health #Career #WithAPhd #PhDChat #phDforum https://www.instagram.com/p/CWJiJPLhsa_/?utm_medium=tumblr

[fromsciencetopharma]

Priority review for Novartis CAR-T cell therapy Kymriah #novartis #cartcells Interested to work in the field of #leukemia as an MSL? Several MSL roles are soon to be advertised on this therapeutic area. Time to reach out to the HR team or the company hiring manager and upskill on your disease knowledge. https://lnkd.in/e6dtadE “The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have both respectively accepted Novartis’ Kymriah for review as a treatment for adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two lines of prior treatment. The FDA also granted the supplemental biologics license application (sBLA) for the CAR-T cell therapy a priority review in this indication. Previously, Kymriah was granted orphan medicinal product designation by the European Commission for FL. The regulatory submission for Novartis’ med are based on data from the Phase II ELARA trial, investigating the efficacy and safety of Kymriah in adults patients with r/r FL. This trial met the primary endpoint with ‘robust responses’ in the heavily pretreated patient population, Novartis said in a statement.” #MSL #FSTP #BCMSLcert #BoardCertifiedMSL #medicalscienceliaison medical science liaison #Medicalaffairs medical affairs #Pharmacist #PHD https://lnkd.in/gN5k8tHp https://www.instagram.com/p/CVjdG-ahsWQ/?utm_medium=tumblr

[fromsciencetopharma]

MSL Medical Activities Learn – Develop – Excel: Continued professional development for Medical Affairs Professionals. Ask your company to include this course in your MSL individual development (IDP) plan. Learn about the top 50 Medical Activities implemented by all major pharmaceutical companies. - Select from over 50 medical activities based on the product needs, CSFs and life cycle: Medical Education, Data Dissemination, Scientific Exchange, Insight Generation, Data Generation, Publication, Access to drugs and more - Learn how best to execute the Medical Activities and obtain maximum output - Stay ahead of your competition Upskill today: https://lnkd.in/ei7dbVt “By far the most comprehensive list of medical activities I have ever seen. Love the practical tips on how to best select and implement them.” Snr MSL – AbbVie “I never knew that there were so many activities to support medical education and data dissemination. A must-have for anyone working on their medical plan” Medical Manager - AZ #MedicalPlan #MedicalActivities #StayOnTop #MSL #MSLTraining #BoardcertifiedMSL #BCMSLcert #BCMSL #AspiringMSL #MedicalAffairs #pharma #MD #PharmD #Pharmacist #Pharmacists #Postdoc #PhD #PhDs #Medicalscienceliaison #MSLS https://www.instagram.com/p/CVgnQCJBvzS/?utm_medium=tumblr

[fromsciencetopharma]

BC-MSLcert: Board-Certification for aspiring MSL The BC-MSLcert is recognized globally by recruiters and pharmaceutical companies as the aspiring MSL standard. Start your MSL career today, become Board-certified MSL. Read how the BC-MSLcert helped hundreds of professionals transition as an MSL. https://lnkd.in/erFr9PT Or if you’d like to know more about the MSL role, join our free MSL webinar on “How to become an MSL without industry experience”: https://lnkd.in/etJsiyw #MSL #BCMSLcert #MSLexcellence #MSLTraining #OnlineMSLTraining #AspiringMSL #MedicalAffairs #pharma #MD #PharmD #MSc #Pharmacist #Pharmacists #Postdoc #postdocs #PhD #Medicalscienceliaison #MSLS #MSLsociety #health #PhDs #PhDChat #phDforum #PhDcareer #PhDstudent #PhDLife #careerdevelopment #FSTP https://www.instagram.com/p/CVgjtBHBtW3/?utm_medium=tumblr